June 8, 2020 / 5:53 PM / a month ago

BRIEF-Neurocrine Biosciences Reports Positive Phase Ii Data For Crinecerfont In Adults With Congenital Adrenal Hyperplasia At Endo Online 2020

June 8 (Reuters) - Neurocrine Biosciences Inc:

* NEUROCRINE BIOSCIENCES INC - REPORTS POSITIVE PHASE II DATA FOR CRINECERFONT IN ADULTS WITH CONGENITAL ADRENAL HYPERPLASIA AT ENDO ONLINE 2020

* NEUROCRINE BIOSCIENCES INC - INITIATION OF GLOBAL REGISTRATIONAL STUDY OF CRINECERFONT IN ADULTS PLANNED FOR H2 2020

* NEUROCRINE BIOSCIENCES INC - CRINECERFONT DEMONSTRATES MEANINGFUL REDUCTIONS IN KEY DISEASE BIOMARKERS AFTER 14 DAYS OF TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below